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1. Introduction 
Dyslipidemia is a change in serum lipids levels, which is associated with increased risk of 
cardiovascular events when are found elevated (American Heart Association, 2002, Sposito 
et al., 2007). Before introduction of antiretroviral therapy (HAART), patients with acquired 
immunodeficiency syndrome (AIDS) developed a dyslipidemia characterized by isolated 
elevation of triglycerides (TG) and decrease in total cholesterol (TC) and its fractions 
(Gkrania-Klotsas & Klotsas, 2007; Mulligan, 2003). With the advent of HAART, especially 
with the use of protease inhibitors (PI), this situation changed to a lipid profile with elevated 
TG, TC, lipoproteins of very low and low density (VLDL-C and LDL-C) and decrease in 
high density lipoprotein (HDL-C), leaving these patients at risk for developing diabetes, 
hypertension and other complications (Chen et al., 2002; Furtado et al., 2007; Garg, 2000; 
Gkrania-Klotsas & Klotsas, 2007; Kotler, 2008; Mulligan, 2003; Sattler, 2008; Segarra-
Newnham, 2002; Schering & Tovar, 2006; Yu et al., 2005). 
Studies estimate that the prevalence of dyslipidemia in patients with HIV (Human 
Immunodeficiency Virus) during use of antiretroviral therapy can vary from 33% to 82% 
and may be influenced by several factors including study type, sample type and time of 
HAART (Gkrania-Klotsas & Klotsas, 2007; Schering & Tovar, 2006; Yu et al., 2005). 
2. HIV lipodystrophy syndrome 
According to UNAIDS and World Health Organization (WHO) (2009) there was a large 
increase in the prevalence of HIV carriers in the world, reaching 33.4 million in 2008, value 
explained by the maintenance of annual incidence and the increase of the survival (Lihn et 
al. 2003; Mallewa et al., 2008). However, was noted a illness pattern change of these patients 
which ever left to be affected by a clinical feature characteristic of opportunistic diseases to 
develop HIV lipodystrophy syndrome (HIVLS) (Kramer et al., 2009; Ministry of Health of  
Brazil, 2008; Samaras et al., 2009; Stankov & Behrens, 2010). 
Body composition abnormalities have been reported in 40-50% of HIV-positive outpatients. 
This proportion is higher in patients receiving antiretroviral therapy. The rate of 
lipodystrophy can be high depending on the characteristics of the cohort (sex, age and 
possibly race), the type and duration of antiretroviral therapy (Grinspoon & Carr, 2005). 
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The HIVLS presents three distinct forms according to distribution pattern: lipoatrophy, with 
fat loss in limbs, face and buttocks; lipohypertrophy, with localized increase of abdominal, 
breast and dorsocervical subcutaneous cellular tissue, besides visceral deposit and lipoma 
formation; and the mixed form with signs of both syndromes earlier (Sattler, 2008; Mello et 
al., 2008) (Figure 1). 
 
 
Legend: A) facial lipoatrophy with facial furrows accentuated, bony prominence, and loss of Bichat’s fat 
(malar fat). B) Lipoatrophy of the lower limbs with prominent veins. C) Visceral lipohypertrophy, with 
increased waist circumference and little subcutaneous tissue. D) Dorsocervical lipohypertrophy. Photos 
of the collection of Dr. Rosana Libonati. 
Fig. 1. Morphological changes in HIV patients with lipodystrophy syndrome, Pará, Brazil. 
In addition to fat distribution alterations, metabolic changes are expressed as a mixed 
dyslipidemia with hypertriglyceridemia, total hypercholesterolemia, low density 
lipoprotein (LDL-C) elevation, reduction of high density lipoprotein (HDL-C), besides the 
induction of insulin resistance culminating in establishment of type II diabetes (Furtado et., 
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2007; Chen et al., 2002; Garg, 2000; Sattler, 2008, Yu et al., 2005). The changes in the 
concentrations of plasma lipids are more observed in patients receiving protease inhibitors 
(PI) (Yu et al., 2005). 
Prospective studies investigating body composition in patients starting HAART for the first 
time have showed increases in fat during the initial months of treatment, followed by a 
progressive declining in the following three years. In one study, the decline was estimated at 
14% per year in white men who received treatment regimens containing 
zidovudine/lamivudine or stavudine/lamivudine plus protease inhibitor or non-nucleoside 
reverse transcriptase inhibitor. In contrast, trunk fat increases initially and then remains 
stable for two or three years, resulting in relative central adiposity. These changes are 
clinically evident in 20 to 35% of patients after about 12 to 24 months of combination 
antiretroviral therapy (Grinspoon & Carr, 2005). 
The type, duration and current use or not of antiretroviral therapy are strongly associated 
with the lipoatrophy severity. Therapy based on two nucleoside analogue reverse 
transcriptase inhibitors and one protease inhibitor has strong association with severe 
lipoatrophy (Mallon et al., 2003). 
Now, the mechanism by which the protease inhibitor causes lipodystrophy remains 
unknown. Several protease inhibitors prevent preadipocytes differentiation and mild to 
moderate apoptosis in subcutaneous adipose tissue. Adipose tissue of patients with 
lipodystrophy has reduced expression of mRNA of several key factors involved in 
adipogenesis, including Sterol regulatory element binding protein (SREBP1c) and 
Peroxisome proliferator-activated receptor gamma (PPARγ). In vitro studies have shown 
that protease inhibitors can inhibit lipogenesis and adipocyte differentiation, stimulate 
lipolysis and prevent nuclear localization of SREBP-1c (Garg, 2000; Grinspoon & Carr, 2005). 
The nucleoside analog more strongly associated with lipoatrophy is stavudine, particularly 
when used in combination with didanosine. Lipoatrophy associated with nucleoside 
analogue may be due in part by mitochondrial injury caused by inhibition of the 
mitochondrial DNA polymerase γ within adipocyte and mitochondrial DNA depletion, 
although the extent and specificity of this effect remains unknown. The nucleoside analogue 
can inhibit adipogenesis and adipocyte differentiation, promote lipolysis and exert 
synergistic toxic effect with protease inhibitors in vitro and in vivo (Grinspoon & Carr, 2005). 
In nine studies assessing risk factors for lipoatrophy, were statistically significant more 
common duration and exposure to thymidine analogues, most commonly stavudine (d4T) 
(6/9), age (5/9), markers of disease severity (CD4/HIV RNA) (5/9), duration of therapy 
(3/9) and Caucasian (3/9). A prospective nonrandomized study in 40 HIV-positive patients 
starting antiretroviral therapy for the first time resulted after an average of 96 weeks, using 
multivariate analysis, that treatment with d4T is an independent factor for lipoatrophy 
(Lichtenstein, 2005). 
In eight studies assessing lipohypertrophy, the most significant risk factors were duration of 
therapy (3/8), a marker of disease severity (3/8), age (3/8) and protease inhibitor use (4/8). 
An additional study evaluating 2258 HIV-positive patients evaluated change in adipose 
tissue for both gender. Logistic regression showed that men have a significantly lower 
adjusted risk than women have (OR: 0.47, CI 95%: from 0.38 to 0.58) and a significantly 
lower risk of lipohypertrophy and mixed redistribution, while the risk of lipoatrophy was 
similar between genders. Therefore, a rigorous multivariate analysis controlling for 
numerous variables reveals multiple risk factors, suggesting that the pathogenic mechanism 
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for fat redistribution seems to be the result of complex interactions between host, disease 
and drugs factors (Lichtenstein, 2005). 
As for the diagnosis of HIVLS, there is not one standard pattern used to subjective body 
changes mentioned by the patients, anthropometric measurements and metabolic changes 
demonstrated in fasting laboratory tests (Diehl et al., 2008). Other tests that assist in 
conducting the HIVLS patients are: bone densitometry, for the investigation of 
osteopenia/osteoporosis; Dual-emission X-ray absorptiometry (DEXA), which allows an 
analysis of body composition, especially fat in the limbs, Computed Tomography, to 
observe presence of visceral fat deposits, and upper abdominal ultrasound for hepatic 
steatosis assessment (Mallon et al., 2003). 
Therefore, the main consequences of HIVLS are increased cardiovascular risk and 
consequent development of hypertension, diabetes mellitus, atheromatous disease, stroke, 
myocardial infarction (Kramer et al., 2009). Psychological disorders as well as, like stress 
and low self-esteem by stigmatizing body changes (Santos et al., 2005; Seidl & Machado, 
2008), which not cease to be risk factor for these events already mentioned by activation of 
sympathetic and glucocorticoids systems, and neuropeptide Y production potentiating the 
metabolic changes (Licht et al., 2010; Rasmusson et al., 2010). 
3. Pathophysiology of dyslipidemia secondary to antiretroviral therapy 
Since the implementation of antiretroviral therapy (HAART), in the 90s of last century, the 
treatment of AIDS has increased the mean life expectancy of HIV-infected population. Until 
then seen as a death sentence in a matter of short time, the disease have been faced like 
chronic, and with more optimism. However, despite a decrease in morbidity and mortality, 
HAART led to a problem that has become a major challenge that patients with AIDS must 
control: dyslipidemia (Cahn et al., 2010). 
The dyslipidemia associated with HAART has been characteristic of elevated total 
cholesterol (TC), low-density lipoprotein (LDL-C) and triglycerides (TG), in addition to 
decreased high-density lipoprotein (HDL-C), which results in increased predisposition to 
the development of hypertension, insulin resistance, diabetes mellitus and cardiovascular 
complications. There are evidences that cardiovascular manifestations proportions in HIV-
infected patients on HAART are higher than in general population (Almeida et al., 2009). 
This does not mean that the occurrence of dyslipidemia has emerged only with the 
implementation of antiretroviral drugs to treat AIDS. Before the existence of HAART had 
been reported lipid profile changes with high levels of triglycerides and low rate of VLDL-C 
and HDL-C (Sprinz et al., 2010; Grunfeld et al., 1992). 
Several studies investigate ways of relating to HAART the effects of dyslipidemia like type 
of drug used by the patient and how the treatment regimen it has been implemented, but is 
still lacking a precise explanation for the lipid profile origin. Protease inhibitors (PI) are 
associated with dyslipidemia and insulin resistance for a considerable time, specifically 
ritonavir, and a variety of hypotheses (albeit not conclusive) it is presented to explain this 
association (Noor, 2007; Dubé et al., 2003). 
One proposed mechanism to emergence of dyslipidemia is the lipoprotein lipase inhibition 
by PI, responsible for LDL-C increased, due to difficulty in capturing chylomicrons, 
resulting in lower hepatic clearance of triglycerides (Sprinz et al., 2010, as cited in Carr & 
Mooser, 2001). Another hypothesis is that PI has the ability to inhibit steps in lipid 
metabolism by binding to cellular retinoic acid binding protein type 1 (CRABP-1) and 
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related protein receptor LDR-c, resulting in hyperlipidemia by higher release of lipids in the 
circulation. More specifically, the PI on CRABP-1 receptor leads to a reduction of 9-cis 
retinoic acid and dimerization with the receptor activated by peroxisome proliferator-
activated receptor gamma (PPAR-γ), which is involved both in apoptosis of adipocytes and 
in differentiation between these two. (Sprinz et al., 2010; Carr et al., 1998). A third theory, 
restricted to ritonavir, antiretroviral therapy suggests it increases the activity of sterol 
regulatory element binding protein 1 (SREBP-1c), increasing lipogenesis, the rate of VLDL-C 
and apolipoprotein B liver. Thus, the increase in triglycerides caused by ritonavir that could 
be related to elevation in hepatic lipoprotein, inhibiting degradation mediated by 
apolipoprotein B and SREBP-1c in liver (Riddle et al., 2001; Liang et al., 2001). 
As regard the insulin resistance promoted by PI, this class of antiretroviral drugs has been 
related to inhibition of GLUT-4 in the transmembrane transport of glucose, leading to 
reduced glucose uptake mediated by insulin in peripheral tissue (skeletal muscle and 
adipocytes), which can lead the modification of lipid levels (Noor, 2007). The fact that some 
patients had a clinical and laboratory profile more or less flowered depending on the effects 
that PI has on the lipids metabolism may be related to genetics, suggesting that certain 
people are more prone to PI effects through manifestation of certain genes so far not 
identified (Shahmanesh et al., 2001). 
With regard to nucleoside reverse transcriptase inhibitors (NRTIs), it is speculated that can 
lead to reduced synthesis of mitochondrial DNA, leading to decreased oxidative 
phosphorylation, resulting in subcutaneous adipocyte apoptosis, dyslipidemia, and 
increased insulin resistance (Maagaard & Kvale, 2009). The reverse transcriptase inhibitor 
non-nucleoside (NNRTI), particularly Efavirenz, are also related to the onset of metabolic 
disorders, including dyslipidemia – but they have lower participation. When compared to 
patients receiving Nevirapine, patients who make use of Efavirenz have higher levels of 
triglycerides and HDL-C (Sprinz et al., 2010, as cited in Carr et al., 1998). 
The type of antiretroviral used in HAART case amends significantly the lipid profile of 
patient it might be replaced. However, make use of a change in medication or combination 
of drugs (a strategy that appears more practical than prescription of lipid, at least at first 
glance) does not always result in improving lipid metabolism, considering the dyslipidemia 
in HIV infection is related to a multifactorial framework (Sprinz et al., 2010). 
Although there are doubts considering the mechanisms linked to development of 
dyslipidemia in patients receiving HAART, and about assumptions not fully understood, 
this is still the most effective treatment in patients with AIDS and should not be proscribed 
for patients. To minimize risks that dyslipidemia implies to health, we recommend the same 
precautions, both dietary and behavioral (avoiding a sedentary lifestyle) and drug 
(statins/fibrates) for the general population. The use of fibrates is primarily indicated for 
reduction of hypertriglyceridemia, while statins are used to reverse the 
hypercholesterolemia. However, must be careful in prescribing of statins, since there is risk 
of drug interactions with HAART (Sprinz et al., 2010). 
4. Treatment of dyslipidemia secondary to antiretroviral therapy 
Hyperlipidemia is a major risk factor for developing of atherosclerosis. Epidemiological 
studies in adults show a direct association between high levels of total cholesterol and LDL 
and the incidence of mortality and morbidity in coronary artery disease (CAD) and is LDL-C a 
predictor of CAD risk at any age, besides low HDL and diabetes mellitus (Giddings, 1999). 
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Dyslipidemia in HIV infection is related to a multifactorial framework (Sprinz et al., 2010), 
so treatment should be done with non-pharmacological and pharmacological measures. 
4.1 Hypercholesterolemia 
4.1.1 Non-pharmacologic therapy 
The HIV-infected patients with dyslipidemia they should be screened before using those 
drugs as therapy, with the implementation of the change of lifestyle of these patients 
through diet, exercise, tobacco control, diabetes mellitus and hypertension (Dubé et al., 
2003). In one study, the diet associated with exercise in 11% reduced cholesterol levels of 
patients infected with HIV (Henry et al., 1998). In another study showed that diet 
accompanied by resistance exercise at least three times a week reduced the cholesterol level 
by 18% and triglycerides by 25% (Jones et al., 2001). 
The first measure to be taken will always be non-pharmacologic therapy, unless there is 
urgent need for intervention, as patients at high risk for coronary artery disease (obesity, 
diabetes, family history of cardiovascular disease) and extremely high levels of LDL-C 
greater than 220 mg / dL (Dubé et al., 2003). 
4.1.2 Pharmacological therapy 
The pharmacological treatment for dyslipidemia it is performed with HMG-CoA reductase 
inhibitors, or statins, are the main representatives of pravastatin and atorvastatin groups. 
They have been used extensively in clinical practice as first-line treatment for 
hypercholesterolemia in the general population and in HIV-infected patients, promoting 
reduction of cardiovascular risk in patients without no history of coronary artery disease 
and of progression of coronary artery stenosis with decrease of cardiovascular events 
recurrence, working in primary and secondary, respectively (Dube et al., 2003). 
In one study, patients with altered levels of total cholesterol (TC) and triglycerides (TG), 
using pravastatin 20 mg/day occurring 19% decrease in the level of TC and 37% in the level 
of TG (Baldini et al., 2000). In another study, diet was associated with therapy with 
pravastatin 40 mg/day in patients with TC levels greater than 240 mg/dL, indicating a 17% 
decline in the levels of TC and 19% in the level of LDL-C (Moyle, 2001). Therefore, Palacios 
et al., in 2002, analyzing a group of patients with TC levels greater than 240 mg/dL under 
atorvastatin 10 mg/day was found a 27% decrease in the level of TC, 41% of TG and 37% in 
the LDL-C. 
Thus, statins are the first choice in the treatment of elevated LDL-C (> 220 mg / dL) and 
patients with high total cholesterol associated with hypertriglyceridemia (TG between 200 to 
500 mg/dL), initial dose may be used 20-40 mg of pravastatin or atorvastatin 10 mg 
monitoring possible liver toxicity with laboratory tests (Dube et al., 2003). Protease 
inhibitors and non-nucleoside inhibitors of reverse transcriptase enzyme use in its 
metabolism the cytochrome P450 pathway (Smith et al., 2001), the same route used by 
simvastatin, lovastatin and atorvastatin, then the first two are proscribed to patients under 
antiretroviral therapy and the latter can be used with caution. 
Fibrates are used as second choice in the treatment of hypercholesterolemia. In patients with 
normal TG and elevated LDL-C levels, a slight decrease in LDL-C ranging from 5 to 20% in 
the studies carried out. Therefore, the therapeutic fibrates use should be reserved for 
treatment of hypertriglyceridemia (TG> 500 mg/dL) in these patients (Dube et al., 2003). 
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4.2 Hypertriglyceridemia 
4.2.1 Non-pharmacologic therapy  
The non-pharmacologic therapy should be first applied to all patients with 
hypertriglyceridemia, through modification of lifestyle; diet should be instituted to reduce 
fat intake, weight reduction, reduction or elimination of alcohol intake, smoking cessation 
control of hyperglycemia and diabetes with insulin sensitizers such as metformin. In 
studies, it has been found that diets associated with exercise and resistance training 
promotes decrease of 21% and 27%, respectively, TG levels in HIV-infected patients (Henry 
et al., 1998; Yarashesky et al., 2001). 
Patients who demonstrate extreme elevations in TG level (> 1000 mg / dL) and with a 
history of pancreatitis should be treated associating pharmacologic and non-pharmacologic 
therapy (Dube et al., 2003). 
4.2.2 Pharmacologic therapy 
Drug therapy should be instituted in all patients with TG levels greater than 500 mg/dL with the 
introduction of Gemfibrozil with starting dose of 600 mg half an hour before meals (lunch and 
dinner) or fibrates at a dose 54 to 160 mg/day (Dube et al., 2003). In a study carried out in 
patients with TG levels higher than 400 mg/dL using fibrate dose of 200 mg/day was observed 
14% and 54% decrease of TC and TG levels, respectively (Palácios et al., 2002). Therefore, in 
another study, patients with TG levels higher than 266 mg/dL, using Gemfibrozil 600 mg/day 
associated with diet, evolved with a reduction of TG values in 18% (Miller et al., 2002). 
The use of statins in general is not recommended for the treatment of hypertriglyceridemia 
(TG> 500 mg / dL) alone, is recommended when triglyceride levels are between 200 to 500 
mg/dL associated with increased total cholesterol (Dubé et al., 2003). 
5. Experience of the assistance service of metabolic diseases secondary to 
antiretroviral therapy for patients with dyslipidemia 
Assistance Service of Metabolic Diseases Secondary to Antiretroviral Therapy (HAART) of 
the João de Barros Barreto University Hospital (HUJBB), Brazilian national reference in 
transmissible infectious diseases and AIDS, actually, assist about 99 HIV carriers’ patients 
with lipodystrophy syndrome. Into this service, the authors develop a Project titled 
Lipodystrophy and Antiretroviral Therapy, financed by The State of Pará Research 
Foundation (FAPESPA), Research Program for the Unified Health System (PPSUS). One of 
the Project’s purposes was the implantation of the lipodystrophy ambulatory care. 
The HUJBB lipodystrophy ambulatory care works with team composed by an 
endocrinologist, a nutrition doctoral student, two medicine M.Sc students, four medical 
undergraduate students. The medical accompaniment is performed once a week. In the first 
service is diagnosed the clinical form of lipodystrophy and requested the proper tests (total 
cholesterol, HDL, LDL, triglycerides, fasting glucose test, oral glucose tolerance, insulin, 
abdominal ultrasonography to hepatic steatosis diagnostic and computed tomography for 
evaluation of visceral lipohypertrophy and electrocardiogram). The first patient's return is 
around 45 days and subsequently every three months for medical accompaniment. Each 
medical consultation is also performed medical history, measurement of blood pressure, 
heart auscultation, anthropometric evaluation (measurements of weight, height, skin folds) 
and bioimpedance. In addition, if need be the patient is referred to other professionals of the 
multidisciplinary team HUJBB. 
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Of the accompanied patients with lipodystrophy syndrome in this ambulatory care, 77%  
(n = 77) have dyslipidemia and presents the following profile: 67.9% were male, mean age of 
44.5 years, average time of HIV infection of 8, 3 years, average time of use of antiretroviral 
therapy for 6.9 years and body mass index of 24.5 kg/m2. Regarding risk factors, it is 
observed that 18.2% are smokers, 40.3% alcoholics, 71.4% sedentary and 45.5% had hepatic 
steatosis. Regarding the classification of nutritional status (WHO, 1995) 58.4% are eutrophic, 
thin 6.5% and 35.1% overweight/obesity. Among the co morbidities studied, it appears that 
24.7% and 21.1% are hypertensive and diabetics, respectively. When stratifying the 
lipodystrophy syndrome, according to the clinical manifestations, 35.1%, 10.4% and 54.5% of 
patients had lipoatrophy, hypertrophy and mixed syndrome, respectively. Concerning 
average serum lipid levels, there is high levels blood of cholesterol and triglycerides, low 
HDL-C, and LDL-C within the normal range. In regard to dyslipidemia classification 
(Sposito et al., 2007), have been observed that 48.7% of patients have mixed hyperlipidemia, 
32.9% hypertriglyceridemia, low HDL-C 10.5% and 7.9% isolated hypercholesterolemia 
(Table 1 and 2). In the assessment of cardiovascular risk by Framingham Risk Score was 
found that more than 30% of the sample had medium and high cardiovascular risk. 
 
Variables Total Sample n %
Male 52 67.5 
Female 25 32.5 
Smoking 77 14 18.2 
Alcoholism 77 31 40.3 
Sedentary 77 55 71.4 
Diabetes mellitus 77 17 21.1 
SH * 77 19 24.7 
Family history 
Diabetes  77 37 48.1 
Hypertension 77 55 71.4 
Dyslipidemia 72 28 38.9 
Hepatic steatosis 66 30 45.5 
Nutritional status** 76
Thinness** 05 6.6
Eutrophic 44 57.9 
Overweight/Obesity 27 35.5 
Lipodystrophy 77
Lipoatrophy  27 35.1 
Hypertrophy 8 10.4 
Mixed 42 54.5 
Classification of dyslipidemia*** 76
Mixed Hyperlipidemia 37 48.7 
Hypertriglyceridemia 25 32.9 
Low HDL 8 10.5 
Isolated hypercholesterolemia 6 7.9
Legend: SH - systemic hypertension; ** WHO, 1995; *** Sposito et al., 2007 
Table 1. Patients profile with lipodystrophy and dyslipidemia accompanied by the 
Assistance Service of Metabolic Diseases Secondary to Antiretroviral Therapy, João de 
Barros Barreto University Hospital, Pará, Brazil. 
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Variable Total Sample Mean ± SD Median 
Age (years) 77 44.5 ± 9.6 45.0
ART Time (years) 77 6.9 ± 4.1 7.0
Time of HIV (years) 77 8.3 ± 5.4 8.0
BMI (kg/m²) 76 24.5 ± 4.2 23.9
Fasting glucose (mg/dL) 72 103.4 ± 27.7 98.5
Total Cholesterol (mg/dL) 76 218.9 ± 59.7 220.0
Triglycerides (mg/dL) 76 373.3± 393.8 280.5
HDL-c (mg/dL) 60 40.8 ± 13.34 39
  Male HDL-c  36 37.4 ± 11.7 37.0
  Female HDL-c 24 46.0 ±14.2 46.5
LDL-c (mg/dL) 58 115.6 ± 45.4 117.9
Legend: ART – Antiretroviral Therapy, BMI – body mass index, SD standard deviation. 
Table 2. Distribution of mean and median values of some variables in patients with 
lipodystrophy and dyslipidemia accompanied by the Assistance Service of Metabolic Diseases 
Secondary to Antiretroviral Therapy, João de Barros Barreto University Hospital, Pará, Brazil. 
The ambulatory care authors conducted an intervention study with outpatient HIV-positive 
with lipodystrophy syndrome, in use of HAART in the period October 2006 to December 2007. 
Patients were evaluated every quarter for four visits. This study followed all the guidelines 
contained in Resolution 196/1996 of the National Committee for Ethics in Research (CONEP), 
being approved by the Ethics in Human Research of the Center for Tropical Medicine, Federal 
University of Para, according to opinion of approval No. 058/2006, to date of October 19, 2006. 
The sample consisted of patients with positive serology for HIV, use of HAART for at least 12 
months, with clinical diagnosis of lipodystrophy. We selected only adult patients, aged 20 to 
60 years, of both sexes. All were invited and agreed to participate by reading and signing the 
Free and Informed Consent Term - FICT. 
We excluded all patients with mental illness, malignant tumors, and chronic users of 
glucocorticoids, Diabetes Mellitus and dyslipidemia diagnosed before starting HAART and 
those who did not achieve at least three follow-up visits clinical and nutritional care at the 
Ambulatory care of Lipodystrophy HUJBB. 
To collect data we used a treatment protocol for metabolic evaluation, nutritional counseling 
and patient outcomes, among several details registered there were: patient identification, 
socio-economic, personal and family morbidity history, time of HIV diagnosis, time of 
HAART treatment, clinical history and biochemical tests. Among the lipodystrophy 
syndrome metabolic changes were required tests to total serum cholesterol, LDL-C, HDL-C 
and triglycerides for dyslipidemia analysis (Sposito et al., 2007). 
We studied 29 patients, 17 (59%) and 12 (41%), male and females, respectively, with an 
average age of 46.07 (± 9.04) years. In males, the average age was 47.59 (± 7.66) years, 
median 46 years, whereas in females the mean age was 43.92 (± 10.67) years, median 44. The 
most prevalent age group for both sexes was 41 to 50 years. 
In regarding to lipodystrophy syndrome classification, was observed that 11 (37.91%), 2 (6,9%) 
and 16 (55,17%) patients demonstrated lipoatrophy, lipohypertrophy and mixed syndrome, 
respectively. There is no sex association with lipoatrophy and mixed syndrome (p= 0.4138, 
OR= 0.3750, IC 95%= 0.0744 – 1.8891), whilst lipohypertrophy syndrome had predominance in 
females. It is assumed when calculating Odds Ratio to lipohypertrophy presence, was noted 
that female chance present lipohypertrophy is 2.66 times more, However, the results have not 
been significant (p=0.4130, IC 95% 0.5294 a 13.4334), data shown in Figure 2.  
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Fig. 2. Distribution of the lipodystrophy syndrome in relation to sex, Pará, Brazil 2006-2008. 
The HAART temporal analysis showed that there was a growing evolution of lipoatrophy 
and lipohypertrophy presence in association with prolonged use of HAART (p = 0.0485,  
p = 0.0393, respectively). 
Among the 29 patients, 6 were taking hypolipidemic. The lipid profile found in patient’s 
evaluation, including those who had made use hypolipidemic therapy, was no statistically 
significant changes on the total cholesterol and LDL-C, however, for the HDL-C and 
triglycerides had significant differences between the first and last clinical follow-up 
nutritional (Figure 3). 
 
 
Legend: (A) Total cholesterol, (B) LDL-C, (C) and HDL-C (D) triglycerides, distributed by quarters. 
Dependent t-test for paired samples.  
Fig. 3. HIV patients Serum lipids who did not use hypolipidemic, distributed by quarters, 
2006-2008 Para-Brazil.  
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When analyzing only the sample of patients who were taking hypolipidemic (n = 7), there 
was no statistically significant changes in the levels of serum total cholesterol, LDL-C and 
triglycerides (Table 3). 
 
Biochemical 
Tests 
1º 2º 3º 4º p value* 
Cholesterol 
Total 
207.7 
(±40.2) 
264.0 
(±128.2) 
216.7 
(± 69.2) 
219.3 
(±60.9) 
0.6626 
LDL 
cholesterol 
91.7 
(±45.6) 
136.6 
(±56.3) 
108.8 
(±29.6) 
89.7 
(±46.04) 
0.2539 
Triglycerides 597.0 
(±300.1) 
996.0 
(±1300.0) 
488.3 
(±637.6) 
415.0 
(±209.3) 
0.0503 
* Legend: Friedman test. 
Table 3. Comparison of mean only of lipid profile of patients who were taking 
hypolipidemic therapy for the clinical follow-up of four nutritional consultations, Pará, 
Brazil 2006-2008.  
In assessing relation between lipids and lipodystrophy syndrome, there was no significant 
association, as sample data in Table 4. 
 
Lipodystrophy Syndrome
 Lipoatrophy 
N (%) 
Lipohypertrophy 
N (%) 
Mixed 
N (%) 
p value 
Total 
Cholesterol 
    
Normal levels 3 (27.27) 0 (0.00) 7 (43.75) 0.3840 
Abnormal 
levels 
8 (72.73) 2 (100.00) 9 (56.25) 
LDL 
cholesterol 
    
Normal levels 9 (81.82) 1 (50.00) 14 (87.50) 0.4141 
Abnormal 
levels 
2 (18.18) 1 (50.00) 2 (12.50) 
HDL 
cholesterol 
    
Normal levels 1 (9.09) 0 (0.00) 5 (31.25) 0.2849 
Abnormal 
levels 
10 (90.91) 2 (100.00) 11 (68.75) 
Triglycerides     
Normal levels 3 (27.27) 1 (50.00) 5 (31.25) 0.3023 
Abnormal 
levels 
8 (72.73) 1 (50.00) 11 (68.75)  
Legend: N - number of patients. Test: Partitioning Chi-square. 
Table 4. Association between lipid profile and lipodystrophy syndrome, Pará, Brazil 2006-
2008.  
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In assessing comparison of mean of lipid profile of all patients before and after the clinical 
and nutritional intervention (first and fourth visit), there was a significant difference 
between the levels of total cholesterol, LDL-C, HDL-C and triglycerides between the 
lipoatrophy and mixed syndrome (p> 0.05) (Table 5). No analysis was performed on the 
lipohypertrophy syndrome due to be there of only two patients. 
 
 Before After 
 Lipoatrophy Mixed p-value Lipoatrophy Mixed p-value 
Total 
cholesterol 
 
196.91 
(±35.05) 
183.00 
(±41.84) 
0.3744 
198.14 
(± 39.26) 
185.58 
(±45.97) 
0.5538 
LDL 
cholesterol 
112.42 
(±40.61) 
94.54 
(±34.67) 
0.2308 
110.37 
(±50.44) 
86.33 
(±32.10) 
0.2313 
HDL 
cholesterol 
37.91 
(±11.65) 
40.28 
(±15.92) 
0.6809 
42.14 
(±9.25) 
44.92 
(±14.64) 
0.4504 
Triglycerides 299.36 
(±27.77) 
310.75 
(±259.21) 
0.9133 
220.86 
(±193.46) 
218.90 
(±179.92) 
0.9829 
Table 5. Comparison of mean of lipid profile of all patients, including who were taking 
hypolipidemic therapy before and after the intervention in lipodystrophy syndrome, Pará, 
Brazil 2006-2008. 
The manifestation of lipodystrophy syndrome with regard to gender did not present 
significant differences for lipoatrophy or mixed syndrome. However, the syndrome was 
related to female lipohypertrophy corroborating other studies (Galli et al., 2002; Heath et al., 
2002) and disagreeing with most published data has been shown increased risk of 
lipoatrophy syndrome among women. Tien et al. (2003) in prospective study of 
lipodystrophy syndrome risk among HIV-infected women and non-infected observed a risk 
2,1 times more of develop lipoatrophy in infected women with virus than non-infected, 
whereas it did not differ lipohypertrophy syndrome between the two groups and the most 
prevalent de form lipodystrophy was mixed syndrome (81%). Van Griensven et al. (2007) 
evaluated the lipodystrophy syndrome prevalence among patients using stavudine in 
antiretroviral therapy and found lipoatrophy syndrome prevalence in 9.8% of patients on 
stavudine and 4.9% with lipohypertrophy syndrome. The HAART temporal analysis 
showed that there was a growing evolution of the appearance of lipoatrophy and 
lipohypertrophy associated with HAART prolonged use, as demonstrated by studies of 
Lichtenstein et al. (2005) and Goujard et al. (2003). 
As regards the evaluation of metabolic changes associated with use of HAART coupled with 
the treatment of nutritional guidance, it must be pointed out that some factors may have 
affected the outcome of this work as the low adherence to medical treatment, nutrition, 
failure to follow the previous recommendations for achieving of biochemical tests and the 
small sample size of patients available for this study. This difficulty in adhering to medical 
treatment and/or diet therapy was also found by other authors (Quintaes & Garcia, 1999; 
Ceccato et al. 2004; Parenti et al., 2005; Barros et al. 2007; Chencinski & Garcia, 2006). The 
reluctance of patients to nutritional treatment may be related to low purchasing power 
(Barros et al., 2007), cultural and dietary habits proper to the Amazon region, who abuse 
food that are rich in lipids. In addition to psychosocial factors of patients, where the 
prejudice, social isolation and emotional disorders such as anxiety and depression 
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commonly observed in patients infected with HIV make it difficult to change lifestyle 
(personal and food) as suggested by Quintaes & Garcia (1999) Chencinski & Garcia (2006). 
There was also that patients profile evaluated before intervention reflected increase in serum 
total cholesterol and triglycerides, and lowering HDL-C as described in the literature (Caar 
et al. 1998; Hadigan et al. 2006; Having Hofstede et al., 2003; Abreu et al., 2006), disagreeing 
with main studies analyzed only about LDL-C, where most patients remained within 
normal range. Lipid disorders and association with lipodystrophy syndrome were common 
in all patients, especially in mixed syndrome, according to studies by Thiebaut et al. (2000) 
and Haugaard et al. (2005). 
The lipid abnormalities evolution in patients after clinical and nutritional intervention 
during study noted significant changes of lowering triglycerides and increase in HDL-C, 
regardless of hypolipidemic use. The increased levels of HDL-C have been associated with 
decreased cardiovascular risk, as has been discussed in the work of Manninen et al. (1988). 
Where was reported that for every 1% increase in HDL-C was 3% reduction in coronary 
events and Pedersen et al. (1998) who said that for each 1% increase in HDL-C there was 1% 
reduction in coronary events, both independently of changes in LDL-C levels. 
The lipid profile of patients before and after nutritional intervention clinically observed that 
patients who had shown serum levels of triglycerides, total cholesterol and fractions (LDL-C 
and HDL-C) normal at first, had increasing them at the end of treatment. These patients had 
borderline values facilitating risk of increased total cholesterol, LDL-C and triglycerides and 
decreased HDL-C associated with nutrition acceptance less than 75%. Other patients in the 
first consultation showed values above the reference levels for total cholesterol, LDL-C and 
triglycerides as well as lowering HDL-C, reaching normal values due to good acceptance to 
nutritional care. The remaining patients showed levels of total cholesterol, LDL-C fractions, 
HDL-C and triglycerides changed during the research; probably was not able to perceive the 
importance of nutritional treatment. There were also cases of patients who had their lipid 
profile within the normal range, suggesting that not only the use of HAART interfered with 
these metabolic changes, but also other factors may be implicated as genetic predisposition. 
In regarding to lipodystrophy syndrome, the cholesterol and LDL-C means demonstrated it 
more significant in lipoatrophy than mixed syndrome compared before and after 
intervention. Triglyceride levels showed independent growing in despite to lipodystrophy 
syndrome, while HDL-C showed changed levels in mixed syndrome. 
The physiopathology by which HAART determines HIV lipodystrophy syndrome, 
dyslipidemia therefore remains unknown. Second Andrade & Hutz (2002), the lipid serum 
levels are multifactorial characteristics, determinate by genetic and environmental factors, 
highlighting the genetic variability found in those genes that can affect the response to 
drugs used in hyperlipidemia treatment. 
The authors of the lipodystrophy ambulatory care are developing a research paper about a 
case-control study conducted from December 2009 to July 2012. For data collection is being 
performed a clinical, epidemiological and nutritional evaluation where are registered 
information about patient identification, socio-economic conditions, personal and family 
history of morbidity, time of HIV diagnosis, HAART treatment duration, medication used - 
HAART, viral load, CD4 counts, clinical history, biochemical tests for dyslipidemia 
classification, anthropometric analysis and, APOAI and APOAV apolipoprotein 
polymorphism evaluation. This study aims to investigate these polymorphisms in an attempt 
to discover the main causes responsible for this metabolic disorder, the dyslipidemia. 
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6. Conclusion 
The HAART has as one of its major collateral effect the lipodystrophy syndrome. There is 
necessity of more studies to deep into physiopathology of this syndrome; and metabolic and 
cardiovascular complications secondary to HAART. Dyslipidemia stands out as one of the 
most prevalent metabolic changes in patients with HIV, what makes it essential to feasibility 
of research in therapeutic care to clarifying of the clinical management. It is noted that 
nutritional guideline and/or hypolipidemic use, when have there been acceptance to 
treatment, takes place improvements of the lipid profile, can also there be normalization of 
those levels, in particular of the triglyceride levels. However, the adherence neither always 
takes place, what difficult the management of those patients. 
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